Biomedical
Li Feng
Founding Partner
Feng focuses on Deep Tech, TMT, consumption upgrade. He led investments on Three Squirrels, Unity, 360 Finance, Qingtao Energy, Shunshun Education, 2:10 Animation, Easy Parking, Robby, and XtaiPl among others. Previously as a partner at IDG-Accel, he led investments on a series of successful projects, including CreditEase, Zhubajie, Prosper, Tongbanjie, Bilibili, Coinbase, Ripple Labs, Dig Fortune, Helijia, Wangli Finance Group, Yodo Fortune, FraudMetrix, Liulishuo, Wecash, Jiang Xiaobai, Hstyle, baifendian, and bairong. Among them, CreditEase went public in 2015, Zhubajie and Prosper successfully joined Billion Dollar Club. The return of investment at seed stage for Three Squirrels, Tongbanjie, and Wangli Finance Group are now up to 50 times. Feng obtained B.S. in Chemistry from Peking University, and M.S. in Chemistry from University of Rochester.
李丰 峰瑞资本创始合伙人
李丰侧重于高科技、TMT、新消费等领域的投资。他主导投资了三只松鼠、Unity、360金融、顺顺留学、清陶能源、两点十分、Robby、停简单等公司。 加入峰瑞资本前，李丰曾于IDG资本担任合伙人。在此期间，他主导投资的项目包括宜信、猪八戒、铜板街、Bilibili、Coinbase、轻轻家教、挖财、河狸家、英语流利说、同盾科技、Ripple Labs、闪银、江小白、韩都衣舍、百分点、百融等一系列优秀创业公司。 李丰拥有北京大学化学理学学士学位与美国罗彻斯特大学化学理学硕士学位。他获评投中集团“2015年度中国最佳移动互联网产业投资人物TOP10”、华兴资本“2017年度最佳天使投资人”“2016年度影响力投资人”、新浪科技“2017中国顶级投资人排行榜Top50”、36氪“最具创业者欢迎的VC投资人”“新金融&新消费领域10大投资人”。
Lynn Yang
focusing on healthcare investment.
Prior to joining Sequoia Capital in May,2015, Lynn worked at Legend Capital healthcare team. Lynn accomplished investment deals in different area of healthcare industry such as Burning Rock, Cstone,Grail,Hongkong Asia Medical etc. Before setting her foot in venture capital, Lynn worked as business development manager in Johnson & Johnson and product manager at GE Healthcare. Mrs. Yang holds a MBA from Duke University and Master of Clinical Science from Huazhong Technology University.
杨云霞 红杉资本中国基金董事总经理
杨云霞主要专注于医疗健康领域的投资。 2015年5月加入红杉之前，杨云霞女士就职于君联资本医疗健康投资团队，主导完成了医疗健康多个细分行业的项目投资包括燃石医学，基石药业，Grail,香港亚洲医疗等。在此之前，杨女士曾经在美国强生，GE等大型跨国公司工作。 杨云霞女士拥有美国杜克大学(Duke University ) MBA学位及华中科技大学同济医科院临床医学硕士学位。
Qin Yan, PhD
Director, Center for Epigenetics and Biomarkers
Department of Pathology
Co-Leader, Genomics, Genetics & Epigenetics Research Program
Scientific Co-Director, Center for Breast Cancer
Yale Cancer Center
Yale School of Medicine
Dr. Yan is Professor and Director of the Center for Epigenetics and Biomarkers in the Department of Pathology at Yale School of Medicine. He is a Co-Leader of the Genomics, Genetics and Epigenetics Research Program and Scientific Co-Director of the Center for Breast Center at the Yale Cancer Center. He is also a member Yale Stem Cell Center, Yale Center for Immuno-Oncology, and Yale Center for Research on Aging. Dr. Yan directs a research laboratory to elucidate the roles of epigenetic mechanisms that drive tumor initiation and progression and to translate their findings into the clinic. He led the discovery, functional characterization and therapeutic targeting of KDM5 histone demethylases in cancer, including leading a team of ~40 scientists assembled by the NCI Experimental Therapeutics program to develop small molecule inhibitors of KDM5. He made major discoveries on multiple epigenetic regulators of immune evasion and cancer metastasis. Notably, a bromodomain inhibitor NHWD-870 that his team reported has entered phase II clinical trial. Dr. Yan obtained his BS degree from the University of Science and Technology of China. After his PhD training on gene regulation with Drs. Joan and Ronald Conaway at the University of Oklahoma Health Sciences Center, he completed his postdoctoral training on cancer biology with Nobel Laureate Dr. William Kaelin at the Dana-Farber Cancer Institute and Harvard Medical School. He joined Yale faculty in 2008 and served as President of Asian Faculty Association at Yale from 2023-2025. He is currently an Associate Editor of Cancer and Metastasis Reviews. He received many awards including Era of Hope Scholar Award from the DoD Breast Cancer Research Program, Outstanding Investigator Award from the American Society of Investigative Pathology, and is an elected member of the Pluto Society (the American Society of University Pathologists).
Dr. Can Cui
Shareholder, Greenberg Traurig, LLP
Dr. Can Cui focuses his practice on technology transactions, investments and intellectual property (IP) protection in the life sciences and med-tech industries, with a particular emphasis on cross-border deals involving Asia. His work encompasses technology licensing and acquisition, collaboration and strategic partnerships, joint ventures, and various forms of investment. Can frequently represents life sciences and med-tech companies, from startups to multinational corporations, in worldwide and U.S.-China life sciences licensing and collaboration transactions, from target or drug discovery phase to clinical stage and beyond. His representation covers the entire value chain, and includes contract research, manufacture and supply, clinical trials, commercialization and distribution arrangements. In the realm of private equity and venture capital, he regularly conducts IP due diligence and negotiates investment documentation for institutional and individual investors, and emerging and established life sciences and med-tech companies. Additionally, Can advises clients on IP aspects of mergers and acquisitions.
Gang Luo, PhD
Associate Professor of Ophthalmology，Harvard Medical School
Dr.Luo’s past experience as a research engineer, including his work with optics,image processing, and biomedical engineering, has influenced his interest inthe mechanisms of the human visual system. He studies assistive technology forindividuals with visual impairments. In particular, his current research includes the development of portable collision warning devices, includingsmartphone-based technologies, to improve walking mobility. He also studiesdriving behaviors in individuals with visual impairments.
HUI HUANG, PHD, MBA
DRUG DEVELOPMENT VALUE & ACCESS EXPERT FOUNDER & CEO, CSD-PARTNERS LLC HTTPS://CSD-PARTNERS.COM
EXPERIENCES VICE PRESIDENT, HEAD OF GLOBAL VALUE & ACCESS ONCOLOGY • TAKEDA • 2019-2023 HEAD OF HEALTH ECONOMICS AND OUTCOMES RESEARCH (HEOR)•TAKEDA ONCOLOGY/ARIAD/MILLENNIUM-TAKEDA• 2007-2019 SENIOR COMPUTATIONAL BIOLOGIST•GENOME THERAPEUTICS/AMBERGEN• 2000-2007
SERVICES Pre-IND +: BD & partnership; Portfolio & Indication strategy Ph1/2: Innovative trial design, protocol and analysis for Regulatory approval, Pricing & Reimbursement; Early scientific advice, Medical & Value Evidence Generation Plan (VGEP) Peri-launch: Health Technology Assessment (HTA) strategy & filing; Global Value Dossier (GVD) for Market Access and Reimbursement • Post-launch: Real-world data (RWD), evidence generation to optimize life cycle for access and pricing
THOUGHT LEADERSHIP Book Co-author: “Real World Evidence in Drug Development and Evaluation” (published by Taylor and Francis, 2021) Co-author: “Access in the New World”, 2021, https://www.pharmexec.com/view/access-in-the-new-world Co-author: World Economic Forum “A Global Roadmap for Health Informatics Standardization”, 2018
Zhidan Daniel Tu
Zhidan Daniel Tu is the COO and head of BD at Zipcode Bio, where he oversees operations and external collaboration and alliance management. Prior to his current role, he was Senior Director of Business Development and Operations at RVAC Medicines and was Director of Business Development at Legend Biotech. In these roles he led end-to-end licensing activities and managed alliances with key partners. He also led companies’ facility and lab setup, daily operations and management. He participated and contributed to fund raising efforts at those roles. From 2011 to 2017 he served several scientific, management and commercial roles at GenScript, including Head of Corporate Development of SMAB Bispecific Antibody Platform, Head of Global Commercial Team of Discovery Biology Business Unit, Scientific Liaison of US East Region and Technology Head, Scientific Lead of Antibody Department. Dr. Tu is co-founder of Chinese Antibody Society. He was general manager and the 2nd president of the society and currently serve as member of the advisory board. Dr. Tu received his PhD of Immunology from joint training of Case Western Reserve University and West China Hospital of Sichuan University, and bachelor’s degree of Biotechnology from Life Science College of Sichuan University.
HighTech & Finance
Zhou Chengjun
Deputy Director General, Research Bureau of PBoC; Research Scholar and Professor of PBoC
Mr. Zhou Chengjun started his career at the People’s Bank of China (PBoC, China’s Central Bank) in 2003. He worked as a post-doctorate at PBoC’s Research Institute of Banking and Finance from July 2003 to July 2005. From 2005 to 2015, he worked in PBoC’s General Administration Office, writing intensively on central bank policy and drafting key policies and research documents for PBoC. Most critically, he served as the secretary and the academic adviser to Governor Zhou Xiaochuan from September 2009 to April 2015. Mr. Zhou was designated as Deputy Head of the General Administration Office from August 2013 to April 2015. From April 2015 to January 2017, he had been performing as Deputy Director General of the Monetary Policy Department Ⅱ of PBoC. Since January 2017, he has been serving as the deputy head of the Research Bureau of PBoC. And among which, for the whole year of 2017, he was working as a senior research associate and visiting scholar at Harvard Kennedy School. Additionally, Mr. Zhou has also been working as a research scholar and professor at the Research Institute of Banking and Finance of PBoC, and the University of International Business and Economics since 2011. In June 2012, Mr. Zhou Chengjun won the National May Fourth Medal, which is one of the highest national honors to China’s youth. His research area included macroeconomics and monetary policy, reform of China’s economic and financial system, and the RMB internationalization and relevant policies. Since 2000, Mr. Zhou has published nearly seventy academic papers and essays in journals including Social Science in China and Financial Research. He is also the author of A Research on Macroeconomic effect of the Asset Price Fluctuation in China as in Constitutional Transition Period, published by Economic Science Publisher in 2004. Mr. Zhou Chengjun is the member of the China Financial Forum and the special member of China Finance 40 Forum. Born in 1975, Mr. Zhou received his Bachelor Degree in Power Engineering in 1997 and a Master
Song Guo
Chair Professor in the Department of Computer Science and Engineering at the Hong Kong University of Science and Technology
Prof. Guo made fundamental and pioneering contributions to the development of edge AI and cloud-edge computing. He has published many papers in top venues with wide impact in these areas and has been consistently recognized as a Clarivate Highly Cited Researcher. He is the recipient of Edward J. McCluskey Technical Achievement Award (IEEE Computer Society) in 2024, First Prize in Natural Science (China Electronics Society) in 2023, Gold Medal of Geneva Inventions Expo in 2024 & 2023, and over a dozen Best Paper Awards from IEEE/ACM. Prof. Guo is the Editor-in-Chief of IEEE Transactions on Cloud Computing. He has served on IEEE ComSoc Board of Governors, and IEEE Fellow Evaluation Committee for both Compuer and Communications Societies. He has also served as organizing and technical committee chair for many IEEE/ACM conferences, workshops and symposia. Prof. Guo is a Fellow of the Canadian Academy of Engineering, a Member of Academia Europaea, and a Fellow of the IEEE.
郭嵩院士
郭嵩院士现任香港科技大学计算机科学与工程系讲座教授，是分布式计算和边缘人工智能领域国际知名学者，特别是对“边缘计算和边缘智能技术”作出开创性贡献，显著推动了技术进步，成为该领域公认的领导者之一，获得2024年度IEEE计算机协会Edward J. McCluskey技术成就奖， 2024年度上海市科学技术奖自然科学一等奖，2023年度中国电子学会自然科学一等奖，并多次获得日内瓦发明博览会金奖等重要奖项。他现任IEEE Transactions on Cloud Computing主编，在多个国际知名会议任大会主席和程序委员会主席。郭嵩教授现为加拿大工程院院士、欧洲科学院外籍院士、IEEE会士。
Duncan Wong, PhD
Founder and CEO of CryptoBLK Dr Duncan Wong is the Founder and CEO of CryptoBLK, a technology company focusing on building and operating Blockchain enterprise solutions for the global financial market. CryptoBLK is specializing in developing trade finance, and asset management platforms. CryptoBLK also has a Blockchain platform called DLTapp-as-a-Service (DaaS) which supports hybrid deployment on both cloud and on-premises. Before founding CryptoBLK, Dr Wong was in charge of the Financial Technologies (FinTech) Initiative of the largest R&D Center in Hong Kong, the Hong Kong Applied Science and Technology Research Institute (ASTRI). The FinTech Initiative focused on Cybersecurity, Blockchain or Distributed Ledger Technology (DLT), Artificial Intelligence, Big Data Analytics, and Machine Learning. Before joining ASTRI in 2014, Dr Wong had been a professor at the Chinese University of Hong Kong, then the City University of Hong Kong for 12 years, and tenured in the Department of Computer Science at City University of Hong Kong in 2009. Information Security, Cryptography, and Blockchain technologies are his primary R&D interests, in particular, cryptographic systems, encryption and digital signature, and crypto-currencies. Dr Wong has authored over 200 publications in Cryptography and Information Security, and has served as a member including the chair of the program committee for over 100 international conferences in cryptography and information security.
王世松博士
区块科技有限公司（CryptoBLK）的创始人兼首席执行官 王世松博士是区块科技有限公司（CryptoBLK）的创始人兼首席执行官。CryptoBLK是一家专注开发及运营企业级区块链解决方案的技术公司。CryptoBLK的产品包括贸易融资和资产估值及管理平台，并提供DLTapp-as-a-Service（DaaS）的区块链平台服务，支持混合云端和就地部署。 在成立CryptoBLK之前，王博士在香港应用科技研究院（ASTRI）担任副总裁， 带领院内金融科技（FinTech）项目研发，包括网络安全，区块链，人工智能，大数据分析和机器学习。王博士曾任香港城市大学计算机科学系教授 (2003-2015)，博导超过十年，发表二百余篇关于密码学之研究文章与专利。
Raymond Fu
Associate Professor and Serial Entrepreneur, Northeastern University
Raymond Fu is an associate professor at Northeastern University and a serial entrepreneur. His research interests focus on AI: Machine Learning, Computer Vision, Big Data, etc. He is Fellow of SPIE and IAPR. In 2016 he founded Giaran, Inc., a company that leverages advanced artificial intelligence technology developed in his Northeastern University lab with the goal of providing an interactive virtual experience for consumers to find and try on cosmetics products. In 2017, Giaran was acquired by Shiseido Americas Corporation, a subsidiary of the leading global cosmetics company Shiseido Company, Limited.
Wan Li Zhu
Partner at Fairhaven Capital
Wan Li Zhu is an experienced technology venture capital investor. Wan Li has been a Partner with Fairhaven Capital in Boston which has invested over $400M in enterprise software, hardware and consumer sectors. His recent investments have focused on AI-based expertise automation and marketplace platforms. Wan Li is Senior Advisor to Suffolk Construction on corporate venture capital, investing in construction and real estate technology companies. Wan Li founded and runs MIT Alumni Angels, MIT’s official alumni-based startup investment network with presence in Boston, New York, San Francisco and DC. Prior to venture capital, Wan Li ran product development and marketing organizations at Microsoft Dynamics CRM, which became the fastest growing business in the company’s history. He has also spent time at Google in online advertising, at Morgan Stanley in technology investment banking, and at Merrill Lynch in IT. Wan Li is the Executive Chairman of the New England Venture Network and has served as Chairman of MIT Enterprise Forum. Wan Li holds an MBA from Harvard, and Master’s and Bachelor’s degrees in Electrical Engineering and Computer Science from MIT where he completed research at the MIT Media Lab and Lab for Financial Engineering.